Literature DB >> 24815150

Artificial islets from hybrid spheroids of three pancreatic cell lines.

Y H Jo1, I J Jang1, J G Nemeno1, S Lee1, B Y Kim1, B M Nam1, W Yang1, K M Lee1, H Kim1, T Takebe2, Y S Kim3, J I Lee4.   

Abstract

Pancreatic islets have been the focus of recent studies exploring the pathologic mechanisms of diabetes mellitus as well as more effective and radical treatments for this disease. Islet transplantation is a promising therapeutic strategy; however, isolation of pancreatic islets for this purpose has been challenging, because the technique is time consuming and technically difficult, and tissue handling can be variable. Pseudo-islets can be used as an alternative to naïve islets, but require cellular sources or artificial materials. In this study, pancreas-derived cells were used to generate pseudo-islets. Because the pancreas is composed of a variety of cell types, namely α cells, β cells, δ cells, and other pancreatic cells that perform different functions, we used 3 different cell lines-NIT-1 (a β-cell line), α TC1 clone 6 (an α-cell line), and TGP52 (a pancreatic epithelial-like cell line)-which we cocultured in nonadhesive culture plates to produce hybrid cellular spheroids. These pseudo-islets had an oval shape and were morphologically similar to naïve islets; additionally, they expressed and secreted the pancreatic hormones insulin, glucagon, and somatostatin, as confirmed by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay. The results demonstrate that pseudo-islets that mimic naïve islets can be successfully generated by a coculture method. These artificial islets can potentially be used for in vitro tests related to diabetes mellitus, specifically, in drug discovery or for investigating pathology. Moreover, they can be useful for examining basic questions pertaining to cell-cell interactions and tissue development. Crown
Copyright © 2014. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24815150     DOI: 10.1016/j.transproceed.2013.11.074

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes.

Authors:  Fanny Lebreton; Vanessa Lavallard; Kevin Bellofatto; Romain Bonnet; Charles H Wassmer; Lisa Perez; Vakhtang Kalandadze; Antonia Follenzi; Michel Boulvain; Julie Kerr-Conte; David J Goodman; Domenico Bosco; Thierry Berney; Ekaterine Berishvili
Journal:  Nat Commun       Date:  2019-10-03       Impact factor: 14.919

2.  Comparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery.

Authors:  Song Mi Lee; Donghee Kim; Kyung Min Kwak; Phyu Phyu Khin; Oh Kyung Lim; Kwang-Won Kim; Byung-Joon Kim; Hee-Sook Jun
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.